Wolfe Research analyst Deepak Mathivanan maintains Meta Platforms (NASDAQ:META) with a Outperform and raises the price target from $220 to $230.
SVB Leerink Maintains Market Perform on Editas Medicine, Lowers Price Target to $12
SVB Leerink analyst Mani Foroohar maintains Editas Medicine (NASDAQ:EDIT) with a Market Perform and lowers the price target from $14 to $12.